id	sid	tid	token	lemma	pos
dpc-4221	1	1	dermatology	dermatology	NOUN
dpc-4221	1	2	:	:	PUNCT
dpc-4221	1	3	practical	practical	ADJ
dpc-4221	1	4	and	and	CCONJ
dpc-4221	1	5	conceptual	conceptual	ADJ
dpc-4221	1	6	research	research	NOUN
dpc-4221	1	7	letter	letter	NOUN
dpc-4221	2	1	|	|	ADV
dpc-4221	2	2	dermatol	dermatol	ADJ
dpc-4221	2	3	pract	pract	NOUN
dpc-4221	2	4	concept	concept	NOUN
dpc-4221	2	5	.	.	PUNCT
dpc-4221	3	1	2024;14(3):e2024190	2024;14(3):e2024190	NUM
dpc-4221	3	2	1	1	NUM
dpc-4221	3	3	tocilizumab	tocilizumab	NOUN
dpc-4221	3	4	-	-	PUNCT
dpc-4221	3	5	induced	induce	VERB
dpc-4221	3	6	sweet	sweet	ADJ
dpc-4221	3	7	syndrome	syndrome	NOUN
dpc-4221	3	8	in	in	ADP
dpc-4221	3	9	a	a	DET
dpc-4221	3	10	familial	familial	ADJ
dpc-4221	3	11	mediterranean	mediterranean	ADJ
dpc-4221	3	12	fever	fever	NOUN
dpc-4221	3	13	patient	patient	NOUN
dpc-4221	3	14	:	:	PUNCT
dpc-4221	3	15	a	a	DET
dpc-4221	3	16	case	case	NOUN
dpc-4221	3	17	report	report	NOUN
dpc-4221	3	18	yusuf	yusuf	PROPN
dpc-4221	3	19	can	can	AUX
dpc-4221	3	20	edek1	edek1	PROPN
dpc-4221	3	21	,	,	PUNCT
dpc-4221	3	22	derya	derya	PROPN
dpc-4221	3	23	yıldırım2	yıldırım2	PROPN
dpc-4221	3	24	,	,	PUNCT
dpc-4221	3	25	melike	melike	PROPN
dpc-4221	3	26	urgancı3	urgancı3	PROPN
dpc-4221	3	27	,	,	PUNCT
dpc-4221	3	28	betül	betül	NOUN
dpc-4221	3	29	öğüt3	öğüt3	NOUN
dpc-4221	3	30	,	,	PUNCT
dpc-4221	3	31	esra	esra	PROPN
dpc-4221	3	32	adışen1	adışen1	PROPN
dpc-4221	4	1	1	1	NUM
dpc-4221	4	2	department	department	NOUN
dpc-4221	4	3	of	of	ADP
dpc-4221	4	4	dermatology	dermatology	NOUN
dpc-4221	4	5	,	,	PUNCT
dpc-4221	4	6	gazi	gazi	PROPN
dpc-4221	4	7	university	university	PROPN
dpc-4221	4	8	faculty	faculty	NOUN
dpc-4221	4	9	of	of	ADP
dpc-4221	4	10	medicine	medicine	NOUN
dpc-4221	4	11	,	,	PUNCT
dpc-4221	4	12	ankara	ankara	PROPN
dpc-4221	4	13	,	,	PUNCT
dpc-4221	4	14	turkey	turkey	NOUN
dpc-4221	4	15	2	2	NUM
dpc-4221	4	16	division	division	NOUN
dpc-4221	4	17	of	of	ADP
dpc-4221	4	18	rheumatology	rheumatology	NOUN
dpc-4221	4	19	,	,	PUNCT
dpc-4221	4	20	department	department	NOUN
dpc-4221	4	21	of	of	ADP
dpc-4221	4	22	internal	internal	ADJ
dpc-4221	4	23	medicine	medicine	NOUN
dpc-4221	4	24	,	,	PUNCT
dpc-4221	4	25	gazi	gazi	PROPN
dpc-4221	4	26	university	university	PROPN
dpc-4221	4	27	faculty	faculty	NOUN
dpc-4221	4	28	of	of	ADP
dpc-4221	4	29	medicine	medicine	NOUN
dpc-4221	4	30	,	,	PUNCT
dpc-4221	4	31	ankara	ankara	PROPN
dpc-4221	4	32	,	,	PUNCT
dpc-4221	4	33	turkey	turkey	PROPN
dpc-4221	4	34	3	3	NUM
dpc-4221	4	35	department	department	NOUN
dpc-4221	4	36	of	of	ADP
dpc-4221	4	37	pathology	pathology	PROPN
dpc-4221	4	38	,	,	PUNCT
dpc-4221	4	39	gazi	gazi	PROPN
dpc-4221	4	40	university	university	PROPN
dpc-4221	4	41	faculty	faculty	NOUN
dpc-4221	4	42	of	of	ADP
dpc-4221	4	43	medicine	medicine	NOUN
dpc-4221	4	44	,	,	PUNCT
dpc-4221	4	45	ankara	ankara	PROPN
dpc-4221	4	46	,	,	PUNCT
dpc-4221	4	47	turkey	turkey	PROPN
dpc-4221	4	48	key	key	ADJ
dpc-4221	4	49	words	word	NOUN
dpc-4221	4	50	:	:	PUNCT
dpc-4221	4	51	sweet	sweet	ADJ
dpc-4221	4	52	syndrome	syndrome	NOUN
dpc-4221	4	53	,	,	PUNCT
dpc-4221	4	54	tocilizumab	tocilizumab	NOUN
dpc-4221	4	55	citation	citation	NOUN
dpc-4221	4	56	:	:	PUNCT
dpc-4221	4	57	edek	edek	PROPN
dpc-4221	4	58	yc	yc	PROPN
dpc-4221	4	59	,	,	PUNCT
dpc-4221	4	60	yıldırım	yıldırım	PROPN
dpc-4221	4	61	d	d	PROPN
dpc-4221	4	62	,	,	PUNCT
dpc-4221	4	63	urgancı	urgancı	PROPN
dpc-4221	4	64	m	m	PROPN
dpc-4221	4	65	,	,	PUNCT
dpc-4221	4	66	öğüt	öğüt	PROPN
dpc-4221	4	67	b	b	PROPN
dpc-4221	4	68	,	,	PUNCT
dpc-4221	4	69	adışen	adışen	PROPN
dpc-4221	4	70	e.	e.	PROPN
dpc-4221	4	71	tocilizumab	tocilizumab	PROPN
dpc-4221	4	72	-	-	PUNCT
dpc-4221	4	73	induced	induce	VERB
dpc-4221	4	74	sweet	sweet	ADJ
dpc-4221	4	75	syndrome	syndrome	NOUN
dpc-4221	4	76	in	in	ADP
dpc-4221	4	77	a	a	DET
dpc-4221	4	78	familial	familial	ADJ
dpc-4221	4	79	mediterranean	mediterranean	ADJ
dpc-4221	4	80	fever	fever	NOUN
dpc-4221	4	81	patient	patient	NOUN
dpc-4221	4	82	:	:	PUNCT
dpc-4221	4	83	a	a	DET
dpc-4221	4	84	case	case	NOUN
dpc-4221	4	85	report	report	NOUN
dpc-4221	4	86	.	.	PUNCT
dpc-4221	5	1	dermatol	dermatol	NOUN
dpc-4221	5	2	pract	pract	PROPN
dpc-4221	5	3	concept	concept	NOUN
dpc-4221	5	4	.	.	PUNCT
dpc-4221	6	1	2024;14(3):e2024190	2024;14(3):e2024190	X
dpc-4221	6	2	.	.	PUNCT
dpc-4221	6	3	doi	doi	NOUN
dpc-4221	6	4	:	:	PUNCT
dpc-4221	6	5	https://doi.org/10.5826/dpc.1403a190	https://doi.org/10.5826/dpc.1403a190	NOUN
dpc-4221	6	6	accepted	accept	VERB
dpc-4221	6	7	:	:	PUNCT
dpc-4221	6	8	march	march	PROPN
dpc-4221	6	9	14	14	NUM
dpc-4221	6	10	,	,	PUNCT
dpc-4221	6	11	2024	2024	NUM
dpc-4221	6	12	;	;	PUNCT
dpc-4221	6	13	published	publish	VERB
dpc-4221	6	14	:	:	PUNCT
dpc-4221	7	1	july	july	PROPN
dpc-4221	7	2	2024	2024	NUM
dpc-4221	7	3	copyright	copyright	NOUN
dpc-4221	7	4	:	:	PUNCT
dpc-4221	7	5	©	©	PROPN
dpc-4221	7	6	edek	edek	NOUN
dpc-4221	7	7	et	et	PROPN
dpc-4221	7	8	al	al	PROPN
dpc-4221	7	9	.	.	PUNCT
dpc-4221	8	1	this	this	PRON
dpc-4221	8	2	is	be	AUX
dpc-4221	8	3	an	an	DET
dpc-4221	8	4	open	open	ADJ
dpc-4221	8	5	-	-	PUNCT
dpc-4221	8	6	access	access	NOUN
dpc-4221	8	7	article	article	NOUN
dpc-4221	8	8	distributed	distribute	VERB
dpc-4221	8	9	under	under	ADP
dpc-4221	8	10	the	the	DET
dpc-4221	8	11	terms	term	NOUN
dpc-4221	8	12	of	of	ADP
dpc-4221	8	13	the	the	DET
dpc-4221	8	14	creative	creative	ADJ
dpc-4221	8	15	commons	common	NOUN
dpc-4221	8	16	attribution	attribution	NOUN
dpc-4221	8	17	-	-	PUNCT
dpc-4221	8	18	noncommercial	noncommercial	ADJ
dpc-4221	8	19	license	license	NOUN
dpc-4221	8	20	(	(	PUNCT
dpc-4221	8	21	by	by	ADP
dpc-4221	8	22	-	-	PUNCT
dpc-4221	8	23	nc-4.0	nc-4.0	NOUN
dpc-4221	8	24	)	)	PUNCT
dpc-4221	8	25	,	,	PUNCT
dpc-4221	8	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4221	8	27	,	,	PUNCT
dpc-4221	8	28	which	which	PRON
dpc-4221	8	29	permits	permit	VERB
dpc-4221	8	30	unrestricted	unrestricted	ADJ
dpc-4221	8	31	noncommercial	noncommercial	ADJ
dpc-4221	8	32	use	use	NOUN
dpc-4221	8	33	,	,	PUNCT
dpc-4221	8	34	distribution	distribution	NOUN
dpc-4221	8	35	,	,	PUNCT
dpc-4221	8	36	and	and	CCONJ
dpc-4221	8	37	reproduction	reproduction	NOUN
dpc-4221	8	38	in	in	ADP
dpc-4221	8	39	any	any	DET
dpc-4221	8	40	medium	medium	NOUN
dpc-4221	8	41	,	,	PUNCT
dpc-4221	8	42	provided	provide	VERB
dpc-4221	8	43	the	the	DET
dpc-4221	8	44	original	original	ADJ
dpc-4221	8	45	authors	author	NOUN
dpc-4221	8	46	and	and	CCONJ
dpc-4221	8	47	source	source	NOUN
dpc-4221	8	48	are	be	AUX
dpc-4221	8	49	credited	credit	VERB
dpc-4221	8	50	.	.	PUNCT
dpc-4221	9	1	funding	funding	NOUN
dpc-4221	9	2	:	:	PUNCT
dpc-4221	9	3	none	none	NOUN
dpc-4221	9	4	.	.	PUNCT
dpc-4221	10	1	competing	compete	VERB
dpc-4221	10	2	interests	interest	NOUN
dpc-4221	10	3	:	:	PUNCT
dpc-4221	10	4	none	none	NOUN
dpc-4221	10	5	.	.	PUNCT
dpc-4221	11	1	authorship	authorship	NOUN
dpc-4221	11	2	:	:	PUNCT
dpc-4221	11	3	all	all	DET
dpc-4221	11	4	authors	author	NOUN
dpc-4221	11	5	have	have	AUX
dpc-4221	11	6	contributed	contribute	VERB
dpc-4221	11	7	significantly	significantly	ADV
dpc-4221	11	8	to	to	ADP
dpc-4221	11	9	this	this	DET
dpc-4221	11	10	publication	publication	NOUN
dpc-4221	11	11	.	.	PUNCT
dpc-4221	12	1	corresponding	correspond	VERB
dpc-4221	12	2	author	author	NOUN
dpc-4221	12	3	:	:	PUNCT
dpc-4221	12	4	yusuf	yusuf	PROPN
dpc-4221	12	5	can	can	AUX
dpc-4221	12	6	edek	edek	NOUN
dpc-4221	12	7	,	,	PUNCT
dpc-4221	12	8	gazi	gazi	PROPN
dpc-4221	12	9	universitesi	universitesi	PROPN
dpc-4221	12	10	tip	tip	PROPN
dpc-4221	12	11	fakultesi	fakultesi	PROPN
dpc-4221	12	12	hastanesi	hastanesi	NOUN
dpc-4221	12	13	,	,	PUNCT
dpc-4221	12	14	emniyet	emniyet	NOUN
dpc-4221	12	15	mahallesi	mahallesi	NOUN
dpc-4221	12	16	,	,	PUNCT
dpc-4221	12	17	mevlana	mevlana	NOUN
dpc-4221	12	18	bulvari	bulvari	NOUN
dpc-4221	12	19	,	,	PUNCT
dpc-4221	12	20	no	no	PRON
dpc-4221	12	21	:	:	PUNCT
dpc-4221	12	22	29	29	NUM
dpc-4221	12	23	,	,	PUNCT
dpc-4221	12	24	06560	06560	NUM
dpc-4221	12	25	ankara	ankara	PROPN
dpc-4221	12	26	/	/	SYM
dpc-4221	12	27	turkey	turkey	PROPN
dpc-4221	12	28	.	.	PUNCT
dpc-4221	13	1	telephone	telephone	NOUN
dpc-4221	13	2	number	number	NOUN
dpc-4221	13	3	:	:	PUNCT
dpc-4221	13	4	+903122026129/+905062818274	+903122026129/+905062818274	NOUN
dpc-4221	13	5	.	.	PUNCT
dpc-4221	13	6	e	e	NOUN
dpc-4221	13	7	-	-	NOUN
dpc-4221	13	8	mail	mail	NOUN
dpc-4221	13	9	:	:	PUNCT
dpc-4221	13	10	yusuf-can-35@hotmail.com	yusuf-can-35@hotmail.com	X
dpc-4221	13	11	introduction	introduction	NOUN
dpc-4221	13	12	sweet	sweet	ADJ
dpc-4221	13	13	syndrome	syndrome	NOUN
dpc-4221	13	14	is	be	AUX
dpc-4221	13	15	a	a	DET
dpc-4221	13	16	rare	rare	ADJ
dpc-4221	13	17	neutrophilic	neutrophilic	ADJ
dpc-4221	13	18	dermatosis	dermatosis	NOUN
dpc-4221	13	19	characterized	characterize	VERB
dpc-4221	13	20	by	by	ADP
dpc-4221	13	21	painful	painful	ADJ
dpc-4221	13	22	,	,	PUNCT
dpc-4221	13	23	edematous	edematous	ADJ
dpc-4221	13	24	,	,	PUNCT
dpc-4221	13	25	and	and	CCONJ
dpc-4221	13	26	erythematous	erythematous	ADJ
dpc-4221	13	27	papules	papule	NOUN
dpc-4221	13	28	,	,	PUNCT
dpc-4221	13	29	plaques	plaque	NOUN
dpc-4221	13	30	,	,	PUNCT
dpc-4221	13	31	or	or	CCONJ
dpc-4221	13	32	nodules	nodule	NOUN
dpc-4221	13	33	.	.	PUNCT
dpc-4221	14	1	the	the	DET
dpc-4221	14	2	disease	disease	NOUN
dpc-4221	14	3	can	can	AUX
dpc-4221	14	4	be	be	AUX
dpc-4221	14	5	categorized	categorize	VERB
dpc-4221	14	6	into	into	ADP
dpc-4221	14	7	three	three	NUM
dpc-4221	14	8	main	main	ADJ
dpc-4221	14	9	groups	group	NOUN
dpc-4221	14	10	:	:	PUNCT
dpc-4221	14	11	classical	classical	ADJ
dpc-4221	14	12	sweet	sweet	ADJ
dpc-4221	14	13	syndrome	syndrome	NOUN
dpc-4221	14	14	,	,	PUNCT
dpc-4221	14	15	malignancy	malignancy	NOUN
dpc-4221	14	16	-	-	PUNCT
dpc-4221	14	17	related	relate	VERB
dpc-4221	14	18	sweet	sweet	ADJ
dpc-4221	14	19	syndrome	syndrome	NOUN
dpc-4221	14	20	,	,	PUNCT
dpc-4221	14	21	and	and	CCONJ
dpc-4221	14	22	drug	drug	NOUN
dpc-4221	14	23	-	-	PUNCT
dpc-4221	14	24	related	relate	VERB
dpc-4221	14	25	sweet	sweet	ADJ
dpc-4221	14	26	syndrome	syndrome	NOUN
dpc-4221	14	27	.	.	PUNCT
dpc-4221	15	1	although	although	SCONJ
dpc-4221	15	2	the	the	DET
dpc-4221	15	3	cause	cause	NOUN
dpc-4221	15	4	of	of	ADP
dpc-4221	15	5	the	the	DET
dpc-4221	15	6	disease	disease	NOUN
dpc-4221	15	7	is	be	AUX
dpc-4221	15	8	not	not	PART
dpc-4221	15	9	fully	fully	ADV
dpc-4221	15	10	known	know	VERB
dpc-4221	15	11	in	in	ADP
dpc-4221	15	12	most	most	ADJ
dpc-4221	15	13	cases	case	NOUN
dpc-4221	15	14	,	,	PUNCT
dpc-4221	15	15	infections	infection	NOUN
dpc-4221	15	16	,	,	PUNCT
dpc-4221	15	17	malignancies	malignancy	NOUN
dpc-4221	15	18	,	,	PUNCT
dpc-4221	15	19	drugs	drug	NOUN
dpc-4221	15	20	,	,	PUNCT
dpc-4221	15	21	and	and	CCONJ
dpc-4221	15	22	inflammatory	inflammatory	ADJ
dpc-4221	15	23	diseases	disease	NOUN
dpc-4221	15	24	can	can	AUX
dpc-4221	15	25	be	be	AUX
dpc-4221	15	26	triggering	trigger	VERB
dpc-4221	15	27	factors	factor	NOUN
dpc-4221	15	28	.	.	PUNCT
dpc-4221	16	1	drug	drug	NOUN
dpc-4221	16	2	-	-	PUNCT
dpc-4221	16	3	related	relate	VERB
dpc-4221	16	4	sweet	sweet	ADJ
dpc-4221	16	5	syndrome	syndrome	NOUN
dpc-4221	16	6	is	be	AUX
dpc-4221	16	7	a	a	DET
dpc-4221	16	8	rare	rare	ADJ
dpc-4221	16	9	subtype	subtype	NOUN
dpc-4221	16	10	of	of	ADP
dpc-4221	16	11	sweet	sweet	ADJ
dpc-4221	16	12	syndrome	syndrome	NOUN
dpc-4221	16	13	and	and	CCONJ
dpc-4221	16	14	was	be	AUX
dpc-4221	16	15	first	first	ADV
dpc-4221	16	16	described	describe	VERB
dpc-4221	16	17	in	in	ADP
dpc-4221	16	18	the	the	DET
dpc-4221	16	19	literature	literature	NOUN
dpc-4221	16	20	after	after	ADP
dpc-4221	16	21	the	the	DET
dpc-4221	16	22	use	use	NOUN
dpc-4221	16	23	of	of	ADP
dpc-4221	16	24	trimethoprim	trimethoprim	ADJ
dpc-4221	16	25	/	/	SYM
dpc-4221	16	26	sulfamethoxazole	sulfamethoxazole	NOUN
dpc-4221	16	27	.	.	PUNCT
dpc-4221	17	1	over	over	ADP
dpc-4221	17	2	time	time	NOUN
dpc-4221	17	3	,	,	PUNCT
dpc-4221	17	4	drug	drug	NOUN
dpc-4221	17	5	-	-	PUNCT
dpc-4221	17	6	related	relate	VERB
dpc-4221	17	7	sweet	sweet	ADJ
dpc-4221	17	8	syndrome	syndrome	NOUN
dpc-4221	17	9	cases	case	NOUN
dpc-4221	17	10	induced	induce	VERB
dpc-4221	17	11	by	by	ADP
dpc-4221	17	12	antibiotics	antibiotic	NOUN
dpc-4221	17	13	,	,	PUNCT
dpc-4221	17	14	antivirals	antiviral	NOUN
dpc-4221	17	15	,	,	PUNCT
dpc-4221	17	16	antineoplastics	antineoplastic	NOUN
dpc-4221	17	17	,	,	PUNCT
dpc-4221	17	18	retinoids	retinoid	NOUN
dpc-4221	17	19	,	,	PUNCT
dpc-4221	17	20	and	and	CCONJ
dpc-4221	17	21	granulocyte	granulocyte	ADJ
dpc-4221	17	22	colony	colony	NOUN
dpc-4221	17	23	-	-	PUNCT
dpc-4221	17	24	stimulating	stimulate	VERB
dpc-4221	17	25	factor	factor	NOUN
dpc-4221	17	26	(	(	PUNCT
dpc-4221	17	27	g	g	NOUN
dpc-4221	17	28	-	-	PUNCT
dpc-4221	17	29	csf	csf	NOUN
dpc-4221	17	30	)	)	PUNCT
dpc-4221	17	31	have	have	AUX
dpc-4221	17	32	been	be	AUX
dpc-4221	17	33	reported	report	VERB
dpc-4221	17	34	.	.	PUNCT
dpc-4221	18	1	drug	drug	NOUN
dpc-4221	18	2	-	-	PUNCT
dpc-4221	18	3	related	relate	VERB
dpc-4221	18	4	sweet	sweet	ADJ
dpc-4221	18	5	syndrome	syndrome	NOUN
dpc-4221	18	6	usually	usually	ADV
dpc-4221	18	7	develops	develop	VERB
dpc-4221	18	8	within	within	ADP
dpc-4221	18	9	two	two	NUM
dpc-4221	18	10	weeks	week	NOUN
dpc-4221	18	11	after	after	ADP
dpc-4221	18	12	initial	initial	ADJ
dpc-4221	18	13	exposure	exposure	NOUN
dpc-4221	18	14	,	,	PUNCT
dpc-4221	18	15	and	and	CCONJ
dpc-4221	18	16	recurrence	recurrence	NOUN
dpc-4221	18	17	may	may	AUX
dpc-4221	18	18	be	be	AUX
dpc-4221	18	19	observed	observe	VERB
dpc-4221	18	20	with	with	ADP
dpc-4221	18	21	repeated	repeat	VERB
dpc-4221	18	22	exposure	exposure	NOUN
dpc-4221	18	23	[	[	X
dpc-4221	18	24	1	1	NUM
dpc-4221	18	25	]	]	PUNCT
dpc-4221	18	26	.	.	PUNCT
dpc-4221	19	1	in	in	ADP
dpc-4221	19	2	this	this	DET
dpc-4221	19	3	case	case	NOUN
dpc-4221	19	4	report	report	NOUN
dpc-4221	19	5	,	,	PUNCT
dpc-4221	19	6	we	we	PRON
dpc-4221	19	7	present	present	VERB
dpc-4221	19	8	a	a	DET
dpc-4221	19	9	male	male	ADJ
dpc-4221	19	10	patient	patient	NOUN
dpc-4221	19	11	who	who	PRON
dpc-4221	19	12	was	be	AUX
dpc-4221	19	13	followed	follow	VERB
dpc-4221	19	14	up	up	ADP
dpc-4221	19	15	with	with	ADP
dpc-4221	19	16	familial	familial	ADJ
dpc-4221	19	17	mediterranean	mediterranean	ADJ
dpc-4221	19	18	fever	fever	NOUN
dpc-4221	19	19	(	(	PUNCT
dpc-4221	19	20	fmf	fmf	NOUN
dpc-4221	19	21	)	)	PUNCT
dpc-4221	19	22	and	and	CCONJ
dpc-4221	19	23	developed	develop	VERB
dpc-4221	19	24	sweet	sweet	ADJ
dpc-4221	19	25	syndrome	syndrome	NOUN
dpc-4221	19	26	secondary	secondary	ADJ
dpc-4221	19	27	to	to	ADP
dpc-4221	19	28	the	the	DET
dpc-4221	19	29	use	use	NOUN
dpc-4221	19	30	of	of	ADP
dpc-4221	19	31	tocilizumab	tocilizumab	NOUN
dpc-4221	19	32	.	.	PUNCT
dpc-4221	20	1	case	case	NOUN
dpc-4221	20	2	presentation	presentation	NOUN
dpc-4221	20	3	a	a	DET
dpc-4221	20	4	33	33	NUM
dpc-4221	20	5	-	-	PUNCT
dpc-4221	20	6	year	year	NOUN
dpc-4221	20	7	-	-	PUNCT
dpc-4221	20	8	old	old	ADJ
dpc-4221	20	9	male	male	ADJ
dpc-4221	20	10	patient	patient	NOUN
dpc-4221	20	11	presented	present	VERB
dpc-4221	20	12	at	at	ADP
dpc-4221	20	13	our	our	PRON
dpc-4221	20	14	clinic	clinic	NOUN
dpc-4221	20	15	due	due	ADP
dpc-4221	20	16	to	to	ADP
dpc-4221	20	17	painful	painful	ADJ
dpc-4221	20	18	lesions	lesion	NOUN
dpc-4221	20	19	and	and	CCONJ
dpc-4221	20	20	fever	fever	NOUN
dpc-4221	20	21	.	.	PUNCT
dpc-4221	21	1	his	his	PRON
dpc-4221	21	2	past	past	ADJ
dpc-4221	21	3	medical	medical	ADJ
dpc-4221	21	4	history	history	NOUN
dpc-4221	21	5	revealed	reveal	VERB
dpc-4221	21	6	fmf	fmf	NOUN
dpc-4221	21	7	,	,	PUNCT
dpc-4221	21	8	renal	renal	ADJ
dpc-4221	21	9	amyloidosis	amyloidosis	NOUN
dpc-4221	21	10	,	,	PUNCT
dpc-4221	21	11	and	and	CCONJ
dpc-4221	21	12	hypertension	hypertension	NOUN
dpc-4221	21	13	,	,	PUNCT
dpc-4221	21	14	and	and	CCONJ
dpc-4221	21	15	he	he	PRON
dpc-4221	21	16	was	be	AUX
dpc-4221	21	17	taking	take	VERB
dpc-4221	21	18	tocilizumab	tocilizumab	NOUN
dpc-4221	21	19	,	,	PUNCT
dpc-4221	21	20	anakinra	anakinra	NOUN
dpc-4221	21	21	,	,	PUNCT
dpc-4221	21	22	colchicine	colchicine	PROPN
dpc-4221	21	23	,	,	PUNCT
dpc-4221	21	24	and	and	CCONJ
dpc-4221	21	25	nifedipine	nifedipine	ADJ
dpc-4221	21	26	treatments	treatment	NOUN
dpc-4221	21	27	.	.	PUNCT
dpc-4221	22	1	he	he	PRON
dpc-4221	22	2	described	describe	VERB
dpc-4221	22	3	that	that	SCONJ
dpc-4221	22	4	tocilizumab	tocilizumab	NOUN
dpc-4221	22	5	was	be	AUX
dpc-4221	22	6	started	start	VERB
dpc-4221	22	7	three	three	NUM
dpc-4221	22	8	months	month	NOUN
dpc-4221	22	9	prior	prior	ADV
dpc-4221	22	10	for	for	ADP
dpc-4221	22	11	fmf	fmf	NOUN
dpc-4221	22	12	.	.	PUNCT
dpc-4221	23	1	three	three	NUM
dpc-4221	23	2	days	day	NOUN
dpc-4221	23	3	after	after	ADP
dpc-4221	23	4	tocilizumab	tocilizumab	NOUN
dpc-4221	23	5	administration	administration	NOUN
dpc-4221	23	6	,	,	PUNCT
dpc-4221	23	7	painful	painful	ADJ
dpc-4221	23	8	lesions	lesion	NOUN
dpc-4221	23	9	had	have	AUX
dpc-4221	23	10	developed	develop	VERB
dpc-4221	23	11	on	on	ADP
dpc-4221	23	12	the	the	DET
dpc-4221	23	13	legs	leg	NOUN
dpc-4221	23	14	accompanied	accompany	VERB
dpc-4221	23	15	by	by	ADP
dpc-4221	23	16	a	a	DET
dpc-4221	23	17	fever	fever	NOUN
dpc-4221	23	18	exceeding	exceed	VERB
dpc-4221	23	19	38	38	NUM
dpc-4221	23	20	°	°	NOUN
dpc-4221	23	21	c	c	NOUN
dpc-4221	23	22	,	,	PUNCT
dpc-4221	23	23	and	and	CCONJ
dpc-4221	23	24	his	his	PRON
dpc-4221	23	25	complaints	complaint	NOUN
dpc-4221	23	26	recurred	recur	VERB
dpc-4221	23	27	with	with	ADP
dpc-4221	23	28	the	the	DET
dpc-4221	23	29	following	follow	VERB
dpc-4221	23	30	drug	drug	NOUN
dpc-4221	23	31	administrations	administration	NOUN
dpc-4221	23	32	.	.	PUNCT
dpc-4221	24	1	on	on	ADP
dpc-4221	24	2	dermatological	dermatological	ADJ
dpc-4221	24	3	examination	examination	NOUN
dpc-4221	24	4	,	,	PUNCT
dpc-4221	24	5	erythematous	erythematous	ADJ
dpc-4221	24	6	papules	papule	NOUN
dpc-4221	24	7	and	and	CCONJ
dpc-4221	24	8	nodules	nodule	NOUN
dpc-4221	24	9	on	on	ADP
dpc-4221	24	10	the	the	DET
dpc-4221	24	11	legs	leg	NOUN
dpc-4221	24	12	were	be	AUX
dpc-4221	24	13	observed	observe	VERB
dpc-4221	24	14	(	(	PUNCT
dpc-4221	24	15	figure	figure	NOUN
dpc-4221	24	16	1	1	NUM
dpc-4221	24	17	)	)	PUNCT
dpc-4221	24	18	.	.	PUNCT
dpc-4221	25	1	laboratory	laboratory	NOUN
dpc-4221	25	2	evaluation	evaluation	NOUN
dpc-4221	25	3	revealed	reveal	VERB
dpc-4221	25	4	2	2	NUM
dpc-4221	25	5	research	research	NOUN
dpc-4221	25	6	letter	letter	NOUN
dpc-4221	25	7	|	|	ADV
dpc-4221	25	8	dermatol	dermatol	ADJ
dpc-4221	25	9	pract	pract	NOUN
dpc-4221	25	10	concept	concept	NOUN
dpc-4221	25	11	.	.	PUNCT
dpc-4221	26	1	2024;14(3):e2024190	2024;14(3):e2024190	NUM
dpc-4221	26	2	figure	figure	NOUN
dpc-4221	26	3	1	1	NUM
dpc-4221	26	4	.	.	PUNCT
dpc-4221	27	1	(	(	PUNCT
dpc-4221	27	2	a	a	DET
dpc-4221	27	3	,	,	PUNCT
dpc-4221	27	4	b	b	NOUN
dpc-4221	27	5	,	,	PUNCT
dpc-4221	27	6	c	c	NOUN
dpc-4221	27	7	)	)	PUNCT
dpc-4221	27	8	erythematous	erythematous	ADJ
dpc-4221	27	9	papules	papule	NOUN
dpc-4221	27	10	and	and	CCONJ
dpc-4221	27	11	nodules	nodule	NOUN
dpc-4221	27	12	on	on	ADP
dpc-4221	27	13	the	the	DET
dpc-4221	27	14	legs	leg	NOUN
dpc-4221	27	15	.	.	PUNCT
dpc-4221	28	1	figure	figure	NOUN
dpc-4221	28	2	2	2	NUM
dpc-4221	28	3	.	.	PUNCT
dpc-4221	29	1	(	(	PUNCT
dpc-4221	29	2	a	a	PRON
dpc-4221	29	3	,	,	PUNCT
dpc-4221	29	4	b	b	NOUN
dpc-4221	29	5	,	,	PUNCT
dpc-4221	29	6	c	c	NOUN
dpc-4221	29	7	)	)	PUNCT
dpc-4221	29	8	spongiosis	spongiosis	NOUN
dpc-4221	29	9	,	,	PUNCT
dpc-4221	29	10	and	and	CCONJ
dpc-4221	29	11	neutrophil	neutrophil	ADJ
dpc-4221	29	12	accumulation	accumulation	NOUN
dpc-4221	29	13	in	in	ADP
dpc-4221	29	14	the	the	DET
dpc-4221	29	15	epidermis	epidermis	NOUN
dpc-4221	29	16	,	,	PUNCT
dpc-4221	29	17	perivascular	perivascular	ADJ
dpc-4221	29	18	periadnexal	periadnexal	NOUN
dpc-4221	29	19	neutrophil	neutrophil	ADV
dpc-4221	29	20	-	-	PUNCT
dpc-4221	29	21	dominated	dominate	VERB
dpc-4221	29	22	mixed	mixed	ADJ
dpc-4221	29	23	-	-	PUNCT
dpc-4221	29	24	type	type	NOUN
dpc-4221	29	25	inflammation	inflammation	NOUN
dpc-4221	29	26	in	in	ADP
dpc-4221	29	27	the	the	DET
dpc-4221	29	28	dermis	dermis	NOUN
dpc-4221	29	29	(	(	PUNCT
dpc-4221	29	30	h&e	h&e	PROPN
dpc-4221	29	31	,	,	PUNCT
dpc-4221	29	32	x40	x40	PROPN
dpc-4221	29	33	,	,	PUNCT
dpc-4221	29	34	x100	x100	PROPN
dpc-4221	29	35	,	,	PUNCT
dpc-4221	29	36	x100	x100	PROPN
dpc-4221	29	37	)	)	PUNCT
dpc-4221	29	38	.	.	PUNCT
dpc-4221	30	1	leukocytosis	leukocytosis	PROPN
dpc-4221	30	2	,	,	PUNCT
dpc-4221	30	3	neutrophilia	neutrophilia	PROPN
dpc-4221	30	4	,	,	PUNCT
dpc-4221	30	5	and	and	CCONJ
dpc-4221	30	6	elevated	elevated	ADJ
dpc-4221	30	7	acute	acute	NOUN
dpc-4221	30	8	phase	phase	NOUN
dpc-4221	30	9	reactants	reactant	VERB
dpc-4221	30	10	.	.	PUNCT
dpc-4221	31	1	histopathological	histopathological	ADJ
dpc-4221	31	2	examination	examination	NOUN
dpc-4221	31	3	of	of	ADP
dpc-4221	31	4	the	the	DET
dpc-4221	31	5	punch	punch	NOUN
dpc-4221	31	6	biopsy	biopsy	NOUN
dpc-4221	31	7	from	from	ADP
dpc-4221	31	8	the	the	DET
dpc-4221	31	9	erythematous	erythematous	ADJ
dpc-4221	31	10	nodule	nodule	NOUN
dpc-4221	31	11	showed	show	VERB
dpc-4221	31	12	spongiosis	spongiosis	NOUN
dpc-4221	31	13	and	and	CCONJ
dpc-4221	31	14	neutrophil	neutrophil	ADJ
dpc-4221	31	15	accumulation	accumulation	NOUN
dpc-4221	31	16	in	in	ADP
dpc-4221	31	17	the	the	DET
dpc-4221	31	18	epidermis	epidermis	NOUN
dpc-4221	31	19	,	,	PUNCT
dpc-4221	31	20	perivascular	perivascular	ADJ
dpc-4221	31	21	-	-	PUNCT
dpc-4221	31	22	periadnexal	periadnexal	NOUN
dpc-4221	31	23	mixed	mix	VERB
dpc-4221	31	24	-	-	PUNCT
dpc-4221	31	25	type	type	NOUN
dpc-4221	31	26	inflammation	inflammation	NOUN
dpc-4221	31	27	dominated	dominate	VERB
dpc-4221	31	28	with	with	ADP
dpc-4221	31	29	neutrophils	neutrophil	NOUN
dpc-4221	31	30	in	in	ADP
dpc-4221	31	31	the	the	DET
dpc-4221	31	32	dermis	dermis	NOUN
dpc-4221	31	33	(	(	PUNCT
dpc-4221	31	34	figure	figure	NOUN
dpc-4221	31	35	2	2	NUM
dpc-4221	31	36	)	)	PUNCT
dpc-4221	31	37	.	.	PUNCT
dpc-4221	32	1	based	base	VERB
dpc-4221	32	2	on	on	ADP
dpc-4221	32	3	clinical	clinical	ADJ
dpc-4221	32	4	examination	examination	NOUN
dpc-4221	32	5	and	and	CCONJ
dpc-4221	32	6	histopathological	histopathological	ADJ
dpc-4221	32	7	findings	finding	NOUN
dpc-4221	32	8	,	,	PUNCT
dpc-4221	32	9	the	the	DET
dpc-4221	32	10	patient	patient	NOUN
dpc-4221	32	11	was	be	AUX
dpc-4221	32	12	diagnosed	diagnose	VERB
dpc-4221	32	13	with	with	ADP
dpc-4221	32	14	sweet	sweet	ADJ
dpc-4221	32	15	syndrome	syndrome	NOUN
dpc-4221	32	16	.	.	PUNCT
dpc-4221	33	1	following	follow	VERB
dpc-4221	33	2	the	the	DET
dpc-4221	33	3	discontinuation	discontinuation	NOUN
dpc-4221	33	4	of	of	ADP
dpc-4221	33	5	tocilizumab	tocilizumab	NOUN
dpc-4221	33	6	and	and	CCONJ
dpc-4221	33	7	topical	topical	ADJ
dpc-4221	33	8	steroid	steroid	NOUN
dpc-4221	33	9	treatment	treatment	NOUN
dpc-4221	33	10	,	,	PUNCT
dpc-4221	33	11	regression	regression	NOUN
dpc-4221	33	12	of	of	ADP
dpc-4221	33	13	the	the	DET
dpc-4221	33	14	lesions	lesion	NOUN
dpc-4221	33	15	was	be	AUX
dpc-4221	33	16	observed	observe	VERB
dpc-4221	33	17	.	.	PUNCT
dpc-4221	34	1	when	when	SCONJ
dpc-4221	34	2	the	the	DET
dpc-4221	34	3	naranjo	naranjo	PROPN
dpc-4221	34	4	adverse	adverse	ADJ
dpc-4221	34	5	reaction	reaction	NOUN
dpc-4221	34	6	probability	probability	NOUN
dpc-4221	34	7	scale	scale	NOUN
dpc-4221	34	8	calculated	calculate	VERB
dpc-4221	34	9	for	for	ADP
dpc-4221	34	10	tocilizumab	tocilizumab	NOUN
dpc-4221	34	11	was	be	AUX
dpc-4221	34	12	7	7	NUM
dpc-4221	34	13	(	(	PUNCT
dpc-4221	34	14	5–8	5–8	NOUN
dpc-4221	34	15	:	:	PUNCT
dpc-4221	34	16	possible	possible	ADJ
dpc-4221	34	17	)	)	PUNCT
dpc-4221	34	18	,	,	PUNCT
dpc-4221	34	19	and	and	CCONJ
dpc-4221	34	20	the	the	DET
dpc-4221	34	21	patient	patient	NOUN
dpc-4221	34	22	met	meet	VERB
dpc-4221	34	23	all	all	DET
dpc-4221	34	24	diagnostic	diagnostic	ADJ
dpc-4221	34	25	criteria	criterion	NOUN
dpc-4221	34	26	for	for	ADP
dpc-4221	34	27	drug	drug	NOUN
dpc-4221	34	28	-	-	PUNCT
dpc-4221	34	29	related	relate	VERB
dpc-4221	34	30	sweet	sweet	ADJ
dpc-4221	34	31	syndrome	syndrome	NOUN
dpc-4221	34	32	,	,	PUNCT
dpc-4221	34	33	it	it	PRON
dpc-4221	34	34	was	be	AUX
dpc-4221	34	35	accepted	accept	VERB
dpc-4221	34	36	sweet	sweet	ADJ
dpc-4221	34	37	syndrome	syndrome	NOUN
dpc-4221	34	38	had	have	AUX
dpc-4221	34	39	developed	develop	VERB
dpc-4221	34	40	secondary	secondary	ADJ
dpc-4221	34	41	to	to	ADP
dpc-4221	34	42	tocilizumab	tocilizumab	VERB
dpc-4221	34	43	.	.	PUNCT
dpc-4221	35	1	conclusion	conclusion	NOUN
dpc-4221	35	2	increased	increase	VERB
dpc-4221	35	3	cytokines	cytokine	NOUN
dpc-4221	35	4	such	such	ADJ
dpc-4221	35	5	as	as	ADP
dpc-4221	35	6	il-1	il-1	X
dpc-4221	35	7	,	,	PUNCT
dpc-4221	35	8	il-6	il-6	NOUN
dpc-4221	35	9	,	,	PUNCT
dpc-4221	35	10	il-8	il-8	NOUN
dpc-4221	35	11	,	,	PUNCT
dpc-4221	35	12	and	and	CCONJ
dpc-4221	35	13	g	g	NOUN
dpc-4221	35	14	-	-	PUNCT
dpc-4221	35	15	csf	csf	NOUN
dpc-4221	35	16	have	have	VERB
dpc-4221	35	17	a	a	DET
dpc-4221	35	18	role	role	NOUN
dpc-4221	35	19	in	in	ADP
dpc-4221	35	20	the	the	DET
dpc-4221	35	21	pathogenesis	pathogenesis	NOUN
dpc-4221	35	22	of	of	ADP
dpc-4221	35	23	sweet	sweet	ADJ
dpc-4221	35	24	syndrome	syndrome	NOUN
dpc-4221	35	25	,	,	PUNCT
dpc-4221	35	26	and	and	CCONJ
dpc-4221	35	27	successful	successful	ADJ
dpc-4221	35	28	treatment	treatment	NOUN
dpc-4221	35	29	of	of	ADP
dpc-4221	35	30	cases	case	NOUN
dpc-4221	35	31	with	with	ADP
dpc-4221	35	32	the	the	DET
dpc-4221	35	33	inhibition	inhibition	NOUN
dpc-4221	35	34	of	of	ADP
dpc-4221	35	35	cytokines	cytokine	NOUN
dpc-4221	35	36	supports	support	VERB
dpc-4221	35	37	research	research	NOUN
dpc-4221	35	38	letter	letter	NOUN
dpc-4221	36	1	|	|	ADV
dpc-4221	36	2	dermatol	dermatol	ADJ
dpc-4221	36	3	pract	pract	NOUN
dpc-4221	36	4	concept	concept	NOUN
dpc-4221	36	5	.	.	PUNCT
dpc-4221	37	1	2024;14(3):e2024190	2024;14(3):e2024190	NUM
dpc-4221	37	2	3	3	NUM
dpc-4221	37	3	this	this	DET
dpc-4221	37	4	role	role	NOUN
dpc-4221	38	1	[	[	X
dpc-4221	38	2	1	1	NUM
dpc-4221	38	3	-	-	SYM
dpc-4221	38	4	4	4	NUM
dpc-4221	38	5	]	]	PUNCT
dpc-4221	38	6	.	.	PUNCT
dpc-4221	39	1	however	however	ADV
dpc-4221	39	2	,	,	PUNCT
dpc-4221	39	3	in	in	ADP
dpc-4221	39	4	the	the	DET
dpc-4221	39	5	literature	literature	NOUN
dpc-4221	39	6	,	,	PUNCT
dpc-4221	39	7	paradoxically	paradoxically	ADV
dpc-4221	39	8	developed	develop	VERB
dpc-4221	39	9	sweet	sweet	ADJ
dpc-4221	39	10	syndrome	syndrome	NOUN
dpc-4221	39	11	cases	case	NOUN
dpc-4221	39	12	have	have	AUX
dpc-4221	39	13	been	be	AUX
dpc-4221	39	14	reported	report	VERB
dpc-4221	39	15	with	with	ADP
dpc-4221	39	16	treatment	treatment	NOUN
dpc-4221	39	17	agents	agent	NOUN
dpc-4221	39	18	that	that	PRON
dpc-4221	39	19	inhibit	inhibit	VERB
dpc-4221	39	20	these	these	DET
dpc-4221	39	21	cytokines	cytokine	NOUN
dpc-4221	39	22	[	[	X
dpc-4221	39	23	5	5	NUM
dpc-4221	39	24	]	]	PUNCT
dpc-4221	39	25	.	.	PUNCT
dpc-4221	40	1	the	the	DET
dpc-4221	40	2	development	development	NOUN
dpc-4221	40	3	of	of	ADP
dpc-4221	40	4	sweet	sweet	ADJ
dpc-4221	40	5	syndrome	syndrome	NOUN
dpc-4221	40	6	in	in	ADP
dpc-4221	40	7	our	our	PRON
dpc-4221	40	8	patient	patient	NOUN
dpc-4221	40	9	after	after	ADP
dpc-4221	40	10	the	the	DET
dpc-4221	40	11	use	use	NOUN
dpc-4221	40	12	of	of	ADP
dpc-4221	40	13	tocilizumab	tocilizumab	NOUN
dpc-4221	40	14	,	,	PUNCT
dpc-4221	40	15	an	an	DET
dpc-4221	40	16	inhibitor	inhibitor	NOUN
dpc-4221	40	17	of	of	ADP
dpc-4221	40	18	il-6	il-6	NOUN
dpc-4221	40	19	,	,	PUNCT
dpc-4221	40	20	which	which	PRON
dpc-4221	40	21	is	be	AUX
dpc-4221	40	22	involved	involve	VERB
dpc-4221	40	23	in	in	ADP
dpc-4221	40	24	the	the	DET
dpc-4221	40	25	pathogenesis	pathogenesis	NOUN
dpc-4221	40	26	of	of	ADP
dpc-4221	40	27	sweet	sweet	ADJ
dpc-4221	40	28	syndrome	syndrome	NOUN
dpc-4221	40	29	,	,	PUNCT
dpc-4221	40	30	brings	bring	VERB
dpc-4221	40	31	to	to	PART
dpc-4221	40	32	mind	mind	VERB
dpc-4221	40	33	the	the	DET
dpc-4221	40	34	idea	idea	NOUN
dpc-4221	40	35	that	that	SCONJ
dpc-4221	40	36	this	this	PRON
dpc-4221	40	37	may	may	AUX
dpc-4221	40	38	be	be	AUX
dpc-4221	40	39	a	a	DET
dpc-4221	40	40	paradoxical	paradoxical	ADJ
dpc-4221	40	41	reaction	reaction	NOUN
dpc-4221	40	42	.	.	PUNCT
dpc-4221	41	1	tocilizumab	tocilizumab	NOUN
dpc-4221	41	2	is	be	AUX
dpc-4221	41	3	a	a	DET
dpc-4221	41	4	recombinant	recombinant	ADJ
dpc-4221	41	5	human	human	ADJ
dpc-4221	41	6	monoclonal	monoclonal	NOUN
dpc-4221	41	7	antibody	antibody	NOUN
dpc-4221	41	8	developed	develop	VERB
dpc-4221	41	9	against	against	ADP
dpc-4221	41	10	the	the	DET
dpc-4221	41	11	il-6	il-6	NOUN
dpc-4221	41	12	receptor	receptor	NOUN
dpc-4221	41	13	and	and	CCONJ
dpc-4221	41	14	is	be	AUX
dpc-4221	41	15	used	use	VERB
dpc-4221	41	16	to	to	PART
dpc-4221	41	17	treat	treat	VERB
dpc-4221	41	18	various	various	ADJ
dpc-4221	41	19	diseases	disease	NOUN
dpc-4221	41	20	such	such	ADJ
dpc-4221	41	21	as	as	ADP
dpc-4221	41	22	rheumatoid	rheumatoid	NOUN
dpc-4221	41	23	arthritis	arthritis	NOUN
dpc-4221	41	24	,	,	PUNCT
dpc-4221	41	25	polymyalgia	polymyalgia	PROPN
dpc-4221	41	26	rheumatica	rheumatica	PROPN
dpc-4221	41	27	,	,	PUNCT
dpc-4221	41	28	and	and	CCONJ
dpc-4221	41	29	temporal	temporal	ADJ
dpc-4221	41	30	arteritis	arteritis	NOUN
dpc-4221	41	31	.	.	PUNCT
dpc-4221	42	1	filippi	filippi	PROPN
dpc-4221	42	2	et	et	PROPN
dpc-4221	42	3	al	al	PROPN
dpc-4221	42	4	.	.	PROPN
dpc-4221	42	5	observed	observe	VERB
dpc-4221	42	6	a	a	DET
dpc-4221	42	7	sweet	sweet	ADJ
dpc-4221	42	8	syndrome	syndrome	NOUN
dpc-4221	42	9	in	in	ADP
dpc-4221	42	10	a	a	DET
dpc-4221	42	11	polymyalgia	polymyalgia	NOUN
dpc-4221	42	12	rheumatica	rheumatica	NOUN
dpc-4221	42	13	patient	patient	ADJ
dpc-4221	42	14	after	after	ADP
dpc-4221	42	15	tocilizumab	tocilizumab	NOUN
dpc-4221	42	16	treatment	treatment	NOUN
dpc-4221	42	17	[	[	X
dpc-4221	42	18	6	6	NUM
dpc-4221	42	19	]	]	PUNCT
dpc-4221	42	20	.	.	PUNCT
dpc-4221	43	1	our	our	PRON
dpc-4221	43	2	aim	aim	NOUN
dpc-4221	43	3	in	in	ADP
dpc-4221	43	4	presenting	present	VERB
dpc-4221	43	5	this	this	DET
dpc-4221	43	6	case	case	NOUN
dpc-4221	43	7	is	be	AUX
dpc-4221	43	8	to	to	PART
dpc-4221	43	9	raise	raise	VERB
dpc-4221	43	10	awareness	awareness	NOUN
dpc-4221	43	11	about	about	ADP
dpc-4221	43	12	the	the	DET
dpc-4221	43	13	cutaneous	cutaneous	ADJ
dpc-4221	43	14	side	side	NOUN
dpc-4221	43	15	effects	effect	NOUN
dpc-4221	43	16	of	of	ADP
dpc-4221	43	17	tocilizumab	tocilizumab	NOUN
dpc-4221	43	18	and	and	CCONJ
dpc-4221	43	19	to	to	PART
dpc-4221	43	20	emphasize	emphasize	VERB
dpc-4221	43	21	the	the	DET
dpc-4221	43	22	clinical	clinical	ADJ
dpc-4221	43	23	features	feature	NOUN
dpc-4221	43	24	of	of	ADP
dpc-4221	43	25	drug	drug	NOUN
dpc-4221	43	26	-	-	PUNCT
dpc-4221	43	27	related	relate	VERB
dpc-4221	43	28	sweet	sweet	ADJ
dpc-4221	43	29	syndrome	syndrome	NOUN
dpc-4221	43	30	.	.	PUNCT
dpc-4221	44	1	references	reference	NOUN
dpc-4221	44	2	1	1	NUM
dpc-4221	44	3	.	.	PUNCT
dpc-4221	44	4	shaikh	shaikh	PROPN
dpc-4221	44	5	mb	mb	PROPN
dpc-4221	44	6	,	,	PUNCT
dpc-4221	44	7	krunic	krunic	PROPN
dpc-4221	44	8	al	al	PROPN
dpc-4221	44	9	.	.	PROPN
dpc-4221	44	10	drug	drug	NOUN
dpc-4221	44	11	-	-	PUNCT
dpc-4221	44	12	induced	induce	VERB
dpc-4221	44	13	sweet	sweet	ADJ
dpc-4221	44	14	syndrome	syndrome	NOUN
dpc-4221	44	15	.	.	PUNCT
dpc-4221	44	16	 	 	SPACE
dpc-4221	45	1	j	j	PROPN
dpc-4221	45	2	allergy	allergy	PROPN
dpc-4221	45	3	clin	clin	PROPN
dpc-4221	45	4	immunol	immunol	PROPN
dpc-4221	45	5	pract	pract	PROPN
dpc-4221	45	6	.	.	PUNCT
dpc-4221	46	1	2019;7(7):2400	2019;7(7):2400	X
dpc-4221	46	2	-	-	SYM
dpc-4221	46	3	2401	2401	NUM
dpc-4221	46	4	.	.	PUNCT
dpc-4221	46	5	doi:10.1016	doi:10.1016	PROPN
dpc-4221	46	6	/	/	SYM
dpc-4221	46	7	j.jaip	j.jaip	PROPN
dpc-4221	46	8	.2019.07.002	.2019.07.002	PROPN
dpc-4221	47	1	2	2	X
dpc-4221	47	2	.	.	PUNCT
dpc-4221	47	3	takano	takano	PROPN
dpc-4221	47	4	y	y	PROPN
dpc-4221	47	5	,	,	PUNCT
dpc-4221	47	6	fujino	fujino	PROPN
dpc-4221	47	7	h	h	PROPN
dpc-4221	47	8	,	,	PUNCT
dpc-4221	47	9	yachie	yachie	VERB
dpc-4221	47	10	a	a	PRON
dpc-4221	47	11	,	,	PUNCT
dpc-4221	47	12	sumimoto	sumimoto	NOUN
dpc-4221	47	13	si	si	PROPN
dpc-4221	47	14	.	.	PROPN
dpc-4221	47	15	serum	serum	PROPN
dpc-4221	47	16	cytokine	cytokine	PROPN
dpc-4221	47	17	profile	profile	NOUN
dpc-4221	47	18	in	in	ADP
dpc-4221	47	19	pediatric	pediatric	ADJ
dpc-4221	47	20	sweet	sweet	ADJ
dpc-4221	47	21	’s	’s	PART
dpc-4221	47	22	syndrome	syndrome	NOUN
dpc-4221	47	23	:	:	PUNCT
dpc-4221	47	24	a	a	DET
dpc-4221	47	25	case	case	NOUN
dpc-4221	47	26	report	report	NOUN
dpc-4221	47	27	.	.	PUNCT
dpc-4221	47	28	 	 	SPACE
dpc-4221	48	1	j	j	PROPN
dpc-4221	48	2	med	med	PROPN
dpc-4221	48	3	case	case	PROPN
dpc-4221	48	4	rep	rep	PROPN
dpc-4221	48	5	.	.	PROPN
dpc-4221	48	6	2017;11(1):178	2017;11(1):178	NUM
dpc-4221	48	7	.	.	PUNCT
dpc-4221	49	1	published	publish	VERB
dpc-4221	49	2	2017	2017	NUM
dpc-4221	49	3	jul	jul	PROPN
dpc-4221	49	4	2	2	NUM
dpc-4221	49	5	.	.	PUNCT
dpc-4221	50	1	doi:10.1186	doi:10.1186	PROPN
dpc-4221	50	2	/	/	SYM
dpc-4221	51	1	s13256	s13256	PROPN
dpc-4221	51	2	-017	-017	NOUN
dpc-4221	51	3	-	-	PUNCT
dpc-4221	51	4	1317	1317	NUM
dpc-4221	51	5	-	-	SYM
dpc-4221	51	6	0	0	NUM
dpc-4221	51	7	3	3	NUM
dpc-4221	51	8	.	.	PUNCT
dpc-4221	51	9	cook	cook	NOUN
dpc-4221	51	10	qs	qs	PROPN
dpc-4221	51	11	,	,	PUNCT
dpc-4221	51	12	zdanski	zdanski	PROPN
dpc-4221	51	13	cj	cj	PROPN
dpc-4221	51	14	,	,	PUNCT
dpc-4221	51	15	burkhart	burkhart	PROPN
dpc-4221	51	16	cn	cn	PROPN
dpc-4221	51	17	,	,	PUNCT
dpc-4221	51	18	googe	googe	PROPN
dpc-4221	51	19	pb	pb	PROPN
dpc-4221	51	20	,	,	PUNCT
dpc-4221	51	21	thompson	thompson	PROPN
dpc-4221	51	22	p	p	X
dpc-4221	51	23	,	,	PUNCT
dpc-4221	51	24	wu	wu	PROPN
dpc-4221	51	25	ey	ey	PROPN
dpc-4221	51	26	.	.	PROPN
dpc-4221	51	27	idiopathic	idiopathic	ADJ
dpc-4221	51	28	,	,	PUNCT
dpc-4221	51	29	refractory	refractory	NOUN
dpc-4221	51	30	sweet	sweet	ADJ
dpc-4221	51	31	’s	’s	PART
dpc-4221	51	32	syndrome	syndrome	NOUN
dpc-4221	51	33	associated	associate	VERB
dpc-4221	51	34	with	with	ADP
dpc-4221	51	35	common	common	ADJ
dpc-4221	51	36	variable	variable	ADJ
dpc-4221	51	37	immunodeficiency	immunodeficiency	NOUN
dpc-4221	51	38	:	:	PUNCT
dpc-4221	51	39	a	a	DET
dpc-4221	51	40	case	case	NOUN
dpc-4221	51	41	report	report	NOUN
dpc-4221	51	42	and	and	CCONJ
dpc-4221	51	43	literature	literature	NOUN
dpc-4221	51	44	review	review	NOUN
dpc-4221	51	45	.	.	PUNCT
dpc-4221	51	46	  	  	SPACE
dpc-4221	52	1	curr	curr	PROPN
dpc-4221	52	2	allergy	allergy	PROPN
dpc-4221	52	3	asthma	asthma	PROPN
dpc-4221	52	4	rep	rep	PROPN
dpc-4221	52	5	.	.	PROPN
dpc-4221	52	6	2019;19(6):32	2019;19(6):32	PROPN
dpc-4221	52	7	.	.	PUNCT
dpc-4221	53	1	published	publish	VERB
dpc-4221	53	2	2019	2019	NUM
dpc-4221	53	3	may	may	AUX
dpc-4221	53	4	14	14	NUM
dpc-4221	53	5	.	.	PUNCT
dpc-4221	54	1	doi:10.1007	doi:10.1007	VERB
dpc-4221	54	2	/	/	SYM
dpc-4221	54	3	s11882	s11882	NUM
dpc-4221	54	4	-	-	PUNCT
dpc-4221	54	5	019	019	NUM
dpc-4221	54	6	-	-	PUNCT
dpc-4221	54	7	0864	0864	NUM
dpc-4221	54	8	-	-	SYM
dpc-4221	54	9	4	4	NUM
dpc-4221	54	10	4	4	NUM
dpc-4221	54	11	.	.	PUNCT
dpc-4221	55	1	hwang	hwang	PROPN
dpc-4221	55	2	s	s	PROPN
dpc-4221	55	3	,	,	PUNCT
dpc-4221	55	4	son	son	NOUN
dpc-4221	55	5	h	h	PROPN
dpc-4221	55	6	,	,	PUNCT
dpc-4221	55	7	moon	moon	PROPN
dpc-4221	55	8	j	j	PROPN
dpc-4221	55	9	,	,	PUNCT
dpc-4221	55	10	et	et	PROPN
dpc-4221	55	11	al	al	PROPN
dpc-4221	55	12	.	.	PUNCT
dpc-4221	56	1	refractory	refractory	PROPN
dpc-4221	56	2	neuro	neuro	PROPN
dpc-4221	56	3	-	-	PUNCT
dpc-4221	56	4	sweet	sweet	ADJ
dpc-4221	56	5	disease	disease	NOUN
dpc-4221	56	6	successfully	successfully	ADV
dpc-4221	56	7	treated	treat	VERB
dpc-4221	56	8	with	with	ADP
dpc-4221	56	9	tocilizumab	tocilizumab	NOUN
dpc-4221	56	10	and	and	CCONJ
dpc-4221	56	11	mycophenolate	mycophenolate	PROPN
dpc-4221	56	12	mofetil	mofetil	PROPN
dpc-4221	56	13	.	.	PUNCT
dpc-4221	56	14	 	 	SPACE
dpc-4221	56	15	encephalitis	encephalitis	NOUN
dpc-4221	56	16	.	.	PUNCT
dpc-4221	57	1	2021;1(1):20	2021;1(1):20	NUM
dpc-4221	57	2	-	-	SYM
dpc-4221	57	3	24	24	NUM
dpc-4221	57	4	.	.	PUNCT
dpc-4221	57	5	doi:10.47936	doi:10.47936	NOUN
dpc-4221	57	6	/	/	SYM
dpc-4221	57	7	encephalitis	encephalitis	NOUN
dpc-4221	57	8	.2020.00059	.2020.00059	NOUN
dpc-4221	57	9	5	5	X
dpc-4221	57	10	.	.	PUNCT
dpc-4221	57	11	haber	haber	PROPN
dpc-4221	57	12	r	r	PROPN
dpc-4221	57	13	,	,	PUNCT
dpc-4221	57	14	dib	dib	PROPN
dpc-4221	57	15	n	n	CCONJ
dpc-4221	57	16	,	,	PUNCT
dpc-4221	57	17	el	el	PROPN
dpc-4221	57	18	gemayel	gemayel	PROPN
dpc-4221	57	19	m	m	PROPN
dpc-4221	57	20	,	,	PUNCT
dpc-4221	57	21	makhlouf	makhlouf	PROPN
dpc-4221	57	22	m.	m.	NOUN
dpc-4221	57	23	paradoxical	paradoxical	ADJ
dpc-4221	57	24	neutrophilic	neutrophilic	ADJ
dpc-4221	57	25	dermatosis	dermatosis	NOUN
dpc-4221	57	26	induced	induce	VERB
dpc-4221	57	27	by	by	ADP
dpc-4221	57	28	biologics	biologic	NOUN
dpc-4221	57	29	and	and	CCONJ
dpc-4221	57	30	immunosuppressive	immunosuppressive	ADJ
dpc-4221	57	31	drugs	drug	NOUN
dpc-4221	57	32	:	:	PUNCT
dpc-4221	57	33	a	a	DET
dpc-4221	57	34	systematic	systematic	ADJ
dpc-4221	57	35	review	review	NOUN
dpc-4221	57	36	.	.	PUNCT
dpc-4221	57	37	  	  	SPACE
dpc-4221	58	1	j	j	PROPN
dpc-4221	58	2	am	be	AUX
dpc-4221	58	3	acad	acad	ADJ
dpc-4221	58	4	dermatol	dermatol	NOUN
dpc-4221	58	5	.	.	PUNCT
dpc-4221	59	1	2021;85(4):1048	2021;85(4):1048	NUM
dpc-4221	59	2	-	-	PUNCT
dpc-4221	59	3	1049	1049	NUM
dpc-4221	59	4	.	.	PUNCT
dpc-4221	60	1	doi:10.1016	doi:10.1016	PROPN
dpc-4221	60	2	/	/	SYM
dpc-4221	60	3	j.jaad.2021.02.035	j.jaad.2021.02.035	PROPN
dpc-4221	60	4	6	6	NUM
dpc-4221	60	5	.	.	PUNCT
dpc-4221	61	1	filippi	filippi	PROPN
dpc-4221	61	2	f	f	PROPN
dpc-4221	61	3	,	,	PUNCT
dpc-4221	61	4	chessa	chessa	PROPN
dpc-4221	61	5	ma	ma	PROPN
dpc-4221	61	6	,	,	PUNCT
dpc-4221	61	7	patrizi	patrizi	NOUN
dpc-4221	61	8	a	a	PRON
dpc-4221	61	9	,	,	PUNCT
dpc-4221	61	10	baraldi	baraldi	NOUN
dpc-4221	61	11	c	c	NOUN
dpc-4221	61	12	,	,	PUNCT
dpc-4221	61	13	ferrara	ferrara	NOUN
dpc-4221	61	14	f	f	PROPN
dpc-4221	61	15	,	,	PUNCT
dpc-4221	61	16	bardazzi	bardazzi	PROPN
dpc-4221	61	17	f.	f.	PROPN
dpc-4221	61	18	tocilizumab	tocilizumab	PROPN
dpc-4221	61	19	-	-	PUNCT
dpc-4221	61	20	induced	induce	VERB
dpc-4221	61	21	sweet	sweet	ADJ
dpc-4221	61	22	syndrome	syndrome	NOUN
dpc-4221	61	23	in	in	ADP
dpc-4221	61	24	a	a	DET
dpc-4221	61	25	patient	patient	NOUN
dpc-4221	61	26	with	with	ADP
dpc-4221	61	27	polymyalgia	polymyalgia	PROPN
dpc-4221	61	28	rheumatica	rheumatica	PROPN
dpc-4221	61	29	.	.	PUNCT
dpc-4221	61	30	  	  	SPACE
dpc-4221	62	1	dermatol	dermatol	ADJ
dpc-4221	62	2	pract	pract	NOUN
dpc-4221	62	3	concept	concept	NOUN
dpc-4221	62	4	.	.	PUNCT
dpc-4221	63	1	2019;10(1):e2020019	2019;10(1):e2020019	X
dpc-4221	63	2	.	.	PUNCT
dpc-4221	64	1	published	publish	VERB
dpc-4221	64	2	2019	2019	NUM
dpc-4221	64	3	dec	dec	PROPN
dpc-4221	64	4	31	31	NUM
dpc-4221	64	5	.	.	PUNCT
dpc-4221	65	1	doi:10.5826	doi:10.5826	PROPN
dpc-4221	65	2	/	/	SYM
dpc-4221	65	3	dpc	dpc	PROPN
dpc-4221	65	4	.1001a19	.1001a19	PART
dpc-4221	65	5	table	table	NOUN
dpc-4221	65	6	1	1	NUM
dpc-4221	65	7	.	.	PUNCT
dpc-4221	66	1	diagnostic	diagnostic	ADJ
dpc-4221	66	2	criteria	criterion	NOUN
dpc-4221	66	3	for	for	ADP
dpc-4221	66	4	the	the	DET
dpc-4221	66	5	diagnosis	diagnosis	NOUN
dpc-4221	66	6	of	of	ADP
dpc-4221	66	7	drug	drug	NOUN
dpc-4221	66	8	-	-	PUNCT
dpc-4221	66	9	related	relate	VERB
dpc-4221	66	10	sweet	sweet	ADJ
dpc-4221	66	11	syndrome	syndrome	NOUN
dpc-4221	66	12	drug	drug	NOUN
dpc-4221	66	13	induced	induce	VERB
dpc-4221	66	14	sweet	sweet	ADJ
dpc-4221	66	15	syndrome	syndrome	NOUN
dpc-4221	66	16	our	our	PRON
dpc-4221	66	17	case	case	NOUN
dpc-4221	66	18	sudden	sudden	ADJ
dpc-4221	66	19	onset	onset	NOUN
dpc-4221	66	20	of	of	ADP
dpc-4221	66	21	painful	painful	ADJ
dpc-4221	66	22	erythematous	erythematous	ADJ
dpc-4221	66	23	plaque	plaque	NOUN
dpc-4221	66	24	or	or	CCONJ
dpc-4221	66	25	nodule	nodule	NOUN
dpc-4221	66	26	+	+	CCONJ
dpc-4221	66	27	dense	dense	ADJ
dpc-4221	66	28	neutrophilic	neutrophilic	ADJ
dpc-4221	66	29	infiltration	infiltration	NOUN
dpc-4221	66	30	without	without	ADP
dpc-4221	66	31	signs	sign	NOUN
dpc-4221	66	32	of	of	ADP
dpc-4221	66	33	leukocytoclastic	leukocytoclastic	ADJ
dpc-4221	66	34	vasculitis	vasculitis	NOUN
dpc-4221	66	35	in	in	ADP
dpc-4221	66	36	the	the	DET
dpc-4221	66	37	histopathological	histopathological	ADJ
dpc-4221	66	38	examination	examination	NOUN
dpc-4221	66	39	+	+	CCONJ
dpc-4221	66	40	fever	fever	NOUN
dpc-4221	66	41	above	above	ADP
dpc-4221	66	42	38	38	NUM
dpc-4221	66	43	°	°	NOUN
dpc-4221	66	44	c	c	NOUN
dpc-4221	66	45	+	+	CCONJ
dpc-4221	66	46	temporal	temporal	ADJ
dpc-4221	66	47	relationship	relationship	NOUN
dpc-4221	66	48	between	between	ADP
dpc-4221	66	49	drug	drug	NOUN
dpc-4221	66	50	intake	intake	NOUN
dpc-4221	66	51	and	and	CCONJ
dpc-4221	66	52	clinical	clinical	ADJ
dpc-4221	66	53	findings	finding	NOUN
dpc-4221	66	54	+	+	CCONJ
dpc-4221	66	55	regression	regression	NOUN
dpc-4221	66	56	of	of	ADP
dpc-4221	66	57	lesions	lesion	NOUN
dpc-4221	66	58	with	with	ADP
dpc-4221	66	59	discontinuation	discontinuation	NOUN
dpc-4221	66	60	of	of	ADP
dpc-4221	66	61	the	the	DET
dpc-4221	66	62	drug	drug	NOUN
dpc-4221	66	63	or	or	CCONJ
dpc-4221	66	64	systemic	systemic	ADJ
dpc-4221	66	65	steroid	steroid	NOUN
dpc-4221	66	66	treatment	treatment	NOUN
dpc-4221	66	67	+	+	PUNCT